By Kia Jones, PhD, Medical Director, Medlive & Tara Gibson, Senior Medical Director, Medlive
Testing rates for FRα-directed therapy sit at only 18% in community settings. At the ASCO Annual Meeting 2026, Medlive presented data on why community oncologists aren’t adopting FRα-directed therapy at the rate the evidence supports, and what it takes to change that.
The Science: What Our Poster Data Showed
Kia Jones, PhD, Medical Director, Medlive
More than 12,000 American women will die from ovarian cancer in 2026, per the American Cancer Society. Recent therapeutic advancements have the potential to improve outcomes for eligible patients, but adoption remains limited in community oncology settings. To address this barrier, Medlive and faculty from MD Anderson, Duke Cancer Institute, and Stephenson Cancer Center designed this real-world data driven CME intervention. This work was supported by a grant from Genmab.
Click on the poster to access a free downloadable PDF version.
Our research found that FRα testing reached 28% at initial ovarian cancer diagnosis in academic settings but only 18% in community settings. After platinum resistance, both numbers fell further: 15% in academic, and only 11% in community.
Our solution: video-first education that showed promise in moving the needle, with post-test knowledge of FRα’s role as a biomarker increasing 44 points, from 42% pre-activity to 86% post-activity. Furthermore, 42% of learners committed to routinely testing at recurrence; another 42% said they would reevaluate progression-free interval and time-to-first-recurrence.
But the standout takeaway? We found that 39% of learners planned to adopt comprehensive biomarker testing as standard practice, directly impacting the number of patients who may be deemed eligible for FRα-directed therapy.
What the poster could not show, but the questions from the floor made clear, is how much more precision the field wants. Attendees asked whether testing rates differ between gynecologic and medical oncologists, whether intended behavior change looks different in academic versus community settings, and how outcomes break down by learner specialty. These subgroup analyses are already in progress. The demand for them is itself a data point: the people who care most about this space want a sharper map of where the barriers live.
On the Floor at ASCO 2026
Tara Gibson, Senior Medical Director, Medlive
Tara Gibson, Senior MD presenting Medlive’s CME outcomes poster at the ASCO Annual Meeting 2026.
Medlive’s FRα poster attracted an unusually broad audience, a signal that the field recognizes a gap it needs to close.
The FRα space is at an inflection point. One approved therapy, a competitive pipeline, and a community testing infrastructure that hasn’t caught up. Building this program with support from Genmab set the stage: they understood from the start that FRα testing rates gate the eligible patient population, and that community-practice barriers were standing between patients and treatment options. What we didn’t anticipate was the breadth of who showed up, with commercial strategy, HEOR, translational science, and real-world evidence representatives all stopping at the same poster asking detailed questions about testing rates across care settings.
When that cross-section of industry converges around a single outcomes dataset, it reflects where CME sits right now: partners want evidence of practice gaps, evidence of what changes when those gaps are addressed, and evidence that their support led to something measurable. This multi-phase CME intervention delivered it.
Key Takeaways
The reaction at the ASCO Annual Meeting 2026 confirmed something Medlive has built toward for years: outcomes-driven CME produces findings that have the power to shape how a therapeutic area evolves.
For industry partners considering where medical education fits into their launch readiness or MSL strategy, this program is a concrete example of what is possible. The right CME initiative does not just inform clinicians, it generates evidence. Evidence no claims-database or market research study produces on its own: what community practice actually looks like, and what moves when barriers are named and addressed through education.
The gap between what the data showed and the reaction it got in that room tells us the work is far from done. We are glad to be doing it, and glad to be doing it with partners like Genmab who understand why it matters.
The Medlive team at the ASCO Annual Meeting 2026 in Chicago, IL.
This program was supported by an educational grant from Genmab US, Inc.
